



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	319540	UltraBiotic IBS
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	FIT-BioCeuticals Limited	
<b>Postal Address</b>	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
<b>ARTG Start Date</b>	2/07/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . UltraBiotic IBS

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	2/07/2019
---------------------	-------------------------	-----------------------	-----------

### Permitted Indications

Relief of symptoms of medically diagnosed Irritable Bowel Syndrome

Linked indication - Maintain/support general health and wellbeing

Linked indication - Decrease/reduce/relieve abdominal pain/discomfort

Linked indication - Helps reduce occurrence of diarrhoea

Linked indication - Helps reduce occurrence of constipation

Maintain/support healthy digestive system function

Maintain/support digestive system health

Maintain/support intestinal good/beneficial/friendly flora

Helps maintain/support good/beneficial/friendly gut flora during antibiotic use

Help restore good/beneficial/friendly gut flora after antibiotic use

Decrease/reduce/relieve abdominal bloating/distention

### Indication Requirements

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Label statement: Drink plenty of water (or words to that effect).

Label statement: If symptoms persist, talk to your health professional.

Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

Product presentation must not refer to or imply weight loss.

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Label statement: If symptoms persist or worsen talk to your medical practitioner.

Product presentation must only refer to medically diagnosed IBS.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

Pack Size	Poison Schedule
-----------	-----------------

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

Bifidobacterium animalis ssp lactis	14.25 billion CFU
Bifidobacterium bifidum	750 million CFU
Lactobacillus acidophilus	15 billion CFU
Lactobacillus acidophilus	15 billion CFU

**Other Ingredients (Excipients)**

dibasic potassium phosphate

disodium edetate

gellan gum

hypromellose

inulin

magnesium stearate

microcrystalline cellulose

monobasic potassium phosphate

potable water

potassium acetate

silicon dioxide

sucrose

trehalose dihydrate

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.